Forenap wins Anavex 2-73 Ph I trial contract
French neuroscience CRO Forenap Pharma has won the contract to conduct Phase I trials of an Alzheimer’s disease treatment candidate being developed by Swiss drugmaker Anavex Life Sciences.
The drug, Anavex 2-73, is a sigma-1 receptor agonist that has demonstrated neuroprotective efficacy in preclinical trials.
Forenap will be responsible for all aspects of the study, ranging from initial setup and protocol review to site management and monitoring. The contract research organisation (CRO)
Anavex CEO Herve de Kergrohen said: “The selection of a world-class CRO is an important milestone in our product development process and it underscores our commitment to advance ANAVEX 2-73 through Phase I clinical trials."